Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

被引:6
作者
Chiricozzi, Andrea [1 ,2 ,4 ]
Dal Bello, Giacomo [3 ]
Gori, Niccolo [1 ,2 ]
Di Nardo, Lucia [2 ]
Schena, Donatella [3 ]
Caldarola, Giacomo [1 ]
Maurelli, Martina [3 ]
De Simone, Clara [1 ,2 ]
Girolomoni, Giampiero [3 ]
Peris, Ketty [1 ,2 ]
机构
[1] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslaz, Dermatol, Rome, Italy
[3] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy
[4] Fdn Policlin Univ A Gemelli IRCCS, Dermatol, Largo Agostino Gemelli 8, I-00168 Rome, Italy
关键词
Atopic dermatitis; atopic eczema; dose spacing; dupilumab; predictive factors;
D O I
10.1080/09546634.2023.2235041
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings. Objective This study aimed to identify predictive clinical and demographic factors affecting patient selection for dose spacing or treatment withdrawal due to satisfactory response. Materials and methods This retrospective study included adult patients with moderate-to-severe AD treated with dupilumab for at least 16 weeks. Descriptive statistics were performed to analyze demographic and clinical variables. Logistic regression models were used to identify predictor variables. Results A total of 818 adult patients with moderate-to-severe AD was included in the study and 12% (97/818) of them performed dose spacing to 3-4 weeks or treatment withdrawal (8%, 67/818). The presence of non-cutaneous atopic manifestations (OR = 1.59, 95%CI = 1.06-2.38, p = 0.024), prurigo nodularis phenotype (OR = 4.5, 95%CI = 1.87-10.9, p = 0.001) and the age at treatment initiation (OR = 1.82, 95%CI = 1.12-2.94, p = 0.015) were confirmed as the strongest predictors of dose spacing or treatment withdrawal while maintaining dupilumab effectiveness. Conclusion Our findings contribute to define the patient profile that could maintain the therapeutic response after dose spacing or treatment withdrawal. Key message Predicting factors identified patients with dupilumab who could benefit of dose spacing or treatment withdrawal.
引用
收藏
页数:6
相关论文
共 18 条
[1]   Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Gooderham, Melinda ;
Cather, Jennifer C. ;
Weisman, Jamie ;
Pariser, David ;
Simpson, Eric L. ;
Papp, Kim A. ;
Hong, H. Chih-Ho ;
Rubel, Diana ;
Foley, Peter ;
Prens, Errol ;
Griffiths, Christopher E. M. ;
Etoh, Takafumi ;
Pinto, Pedro Herranz ;
Pujol, Ramon M. ;
Szepietowski, Jacek C. ;
Ettler, Karel ;
Kemeny, Lajos ;
Zhu, Xiaoping ;
Akinlade, Bolanle ;
Hultsch, Thomas ;
Mastey, Vera ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Amin, Nikhil ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Stahl, Neil ;
Yancopoulos, George D. ;
Shumel, Brad .
LANCET, 2017, 389 (10086) :2287-2303
[2]   Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy [J].
Chiricozzi, Andrea ;
Di Nardo, Lucia ;
Talamonti, Marina ;
Galluzzo, Marco ;
De Simone, Clara ;
Fabbrocini, Gabriella ;
Marzano, Angelo Valerio ;
Girolomoni, Giampiero ;
Offidani, Annamaria ;
Rossi, Maria Teresa ;
Bianchi, Luca ;
Cristaudo, Antonio ;
Fierro, Maria Teresa ;
Stingeni, Luca ;
Pellacani, Giovanni ;
Argenziano, Giuseppe ;
Patrizi, Annalisa ;
Pigatto, Paolo ;
Romanelli, Marco ;
Savoia, Paola ;
Rubegni, Pietro ;
Foti, Caterina ;
Milanesi, Nicola ;
Fortina, Anna Belloni ;
Bongiorno, Maria Rita ;
Grieco, Teresa ;
Di Nuzzo, Sergio ;
Fargnoli, Maria Concetta ;
Carugno, Andrea ;
Motolese, Alberico ;
Rongioletti, Franco ;
Amerio, Paolo ;
Balestri, Riccardo ;
Potenza, Concetta ;
Micali, Giuseppe ;
Patruno, Cataldo ;
Zalaudek, Iris ;
Lombardo, Maurizio ;
Feliciani, Claudio ;
Antonelli, Flaminia ;
Ferrucci, Silvia Mariel ;
Guarneri, Fabrizio ;
Peris, Ketty .
DERMATITIS, 2022, 33 (03) :E25-E29
[3]   Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo [J].
Chiricozzi, Andrea ;
Maurelli, Martina ;
Gori, Niccolo ;
Argenziano, Giuseppe ;
De Simone, Clara ;
Calabrese, Giulia ;
Girolomoni, Giampiero ;
Peris, Ketty .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) :39-45
[4]   Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy [J].
D'Erme, Angelo Massimiliano ;
Romanelli, Marco ;
Chiricozzi, Andrea .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 :1473-1480
[5]   Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data [J].
de Wijs, L. E. M. ;
Bosma, A. L. ;
Erler, N. S. ;
Hollestein, L. M. ;
Gerbens, L. A. A. ;
Middelkamp-Hup, M. A. ;
Kunkeler, A. C. M. ;
Nijsten, T. E. C. ;
Spuls, P. I. ;
Hijnen, D. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (02) :418-426
[6]   A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis [J].
Fargnoli, M. C. ;
Esposito, M. ;
Ferrucci, S. ;
Girolomoni, G. ;
Offidani, A. ;
Patrizi, A. ;
Peris, K. ;
Costanzo, A. ;
Malara, G. ;
Pellacani, G. ;
Romanelli, M. ;
Amerio, P. ;
Cristaudo, A. ;
Flori, M. L. ;
Motolese, A. ;
Betto, P. ;
Patruno, C. ;
Pigatto, P. ;
Peccianti, C. ;
Stinco, G. ;
Zalaudek, I. ;
Bianchi, L. ;
Boccaletti, V. ;
Cannavo, S. P. ;
Cusano, F. ;
Lembo, S. ;
Mozzillo, R. ;
Gallo, R. ;
Potenza, C. ;
Rongioletti, F. ;
Tiberio, R. ;
Grieco, T. ;
Micali, G. ;
Persechino, S. ;
Pettinato, M. ;
Pucci, S. ;
Stingeni, L. ;
Caruso, C. ;
Argenziano, G. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) :1146-1149
[7]   Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis [J].
Fukushi, S. ;
Yamasaki, K. ;
Aiba, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (05) :990-996
[8]   Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study [J].
Jendoubi, Fatma ;
Shourik, Jason ;
Seneschal, Julien ;
Giordano-Labadie, Francoise ;
Raison-Peyron, Nadia ;
Du-Thanh, Aurelie ;
Tetart, Florence ;
Valois, Aude ;
Droitcourt, Catherine ;
Clement, Aude ;
Nosbaum, Audrey ;
Crepy, Marie Noelle ;
Jachiet, Marie ;
Bouaziz, Jean David ;
Bernier, Claire ;
Soria, Angele ;
Paul, Carle ;
Barbarot, Sebastien ;
Tauber, Marie .
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (04) :602-603
[9]   Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo [J].
Park, Kio ;
Mori, Tomoko ;
Nakamura, Motonobu ;
Tokura, Yoshiki .
EUROPEAN JOURNAL OF DERMATOLOGY, 2011, 21 (01) :135-136
[10]   Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis [J].
Patruno, Cataldo ;
Potestio, Luca ;
Fabbrocini, Gabriella ;
Napolitano, Maddalena .
DERMATOLOGIC THERAPY, 2022, 35 (12)